ReviewKidney international supplements2026
The expanding role of biomarkers in the management of IgA nephropathy.
Review in Kidney international supplements, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
4 citing papers in PubMed.
- Approved therapies in the IgA nephropathy armamentarium: a summary of the evidence.Kidney international supplements · 2026Review
- IgA nephropathy: an overview of the disease, its pathophysiology, and involvement of the gut-kidney axis.Kidney international supplements · 2026Review
- Management of IgA nephropathy and the expanding role of immunomodulation.Kidney international supplements · 2026Review
- IgA nephropathy management: what does the future hold?Kidney international supplements · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
IgA nephropathy is the most prevalent glomerular disease worldwide. To date, a percutaneous kidney biopsy is needed for diagnosis and assessment of disease activity and prognosis. Histology and generic markers of kidney dysfunction, such as proteinuria, hematuria, and estimated glomerular filtration rate, are commonly used to assess kidney damage. Noninvasive biomarkers that can be used to provide diagnostic and prognostic information, enable risk stratification, guide treatment selection, and help monitor treatment response are greatly needed. On the basis of limited data, several promising novel biomarkers specifically related to IgA nephropathy pathophysiology have been proposed and need to be validated and standardized for use in routine clinical care. Once these biomarkers become available, the hope is that they will lead to early diagnosis of IgA nephropathy and provide more accurate prognosis of disease for individual patients. Given the complexity of the pathogenesis of IgA nephropathy, it seems likely that multiple biomarkers will need to be used to optimize patient care.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.